Sep 30, 2025 • Benzinga
SOMEWHAT-BULLISH
6 Stocks Poised For Potential Acquisition In The Next 12 Months, According To Goldman Sachs, Including A 200% YTD Gainer - ( AACT ) , Walt Disney ( NYSE:DIS )
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. The bank reported that the total dollar value of M&A deals has risen 29% year-over-year, with deal volumes in 2025 climbing 8%. The bank projects an additional 15% increase in new ...
Sep 25, 2025 • Motley Fool
SOMEWHAT-BULLISH
3 Reasons to Buy Novo Nordisk Stock Right Now
The pharmaceutical leader is gradually laying the groundwork for a strong rebound.
Sep 18, 2025 • GlobeNewswire
BULLISH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CONSHOHOCKEN, Pa., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it granted equity awards on September ...
Sep 12, 2025 • Benzinga
SOMEWHAT-BULLISH
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday - Adobe ( NASDAQ:ADBE ) , C3.ai ( NYSE:AI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised C3.ai, Inc. AI price target from $16 to $17. UBS analyst Radi Sultan maintained a Neutral rating.
Sep 04, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CONSHOHOCKEN, Pa., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it granted equity awards on September ...
Aug 28, 2025 • Benzinga
SOMEWHAT-BULLISH
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights
EXTON, PA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- The recent approval of Novo Nordisk's Wegovy ( semaglutide 2.4mg ) as the second treatment for metabolic dysfunction-associated steatohepatitis ( MASH ) represents a critical step forward in a condition with a vast patient population and significant ...